The effect of a standardized polyherbal formulation for endometriosis-associated pain: A randomized double-blind placebo-controlled clinical trial

Elham Akhtari, Fataneh Hashem-Dabaghian, A H Jamshidi, Akram Fallah, Majid Dadmehr
In: Journal of Medicinal Plants · 2024 · vol. 23(91) , pp. 75–87 · doi:10.61186/jmp.23.91.75 · W4410361234
article OA: hybrid CC0
📄 Open PDF View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This randomized, double-blind, placebo-controlled trial found that the polyherbal formulation Proscur significantly reduced endometriosis-associated pain and CA-125 levels with minimal side effects in young women.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Background: Dysmenorrhea, dyspareunia and endometriosis-associated pain are considered the main complications in young women with endometriosis.Proscur capsule contains several traditional herbal medicines that have shown anti-inflammatory, antioxidant, anti-androgenic, anti-estrogenic, pelvic pain reducing and analgesic effects in previous pre-clinical and clinical studies.Objective: This study aimed to investigate the clinical efficacy and safety of a standardized polyherbal formulation (proscur) for endometriosis-associated pain in young women with endometriosis.Methods: This study was a single-center, randomized, double-blinded, placebo-controlled, clinical trial.A total of 90 patients aged 20-45 years with endometriosis-associated pain were enrolled.Participants were randomly assigned to the proscur or placebo groups in a ratio of 1:1 and efficacy evaluation was conducted at day 30, 60 and 90.The participants orally administered proscur or placebo two times a day for 12 weeks.The study outcomes were measured based on a change of visual analogue scale (VAS) score and the short form endometriosis health profile questionnaire (EHP-5).Results: We observed an increase in pain relief in women who receive proscur.The serum measures of CA-125 declined in those who received proscur.Intervention was well tolerated, and no serious adverse events occurred.Conclusions: Our study showed that proscur relieved endometriosis-associated pain and CA-125 level with minimal side-effects after treatment.Therefore, proscur combined with standard medical therapy could provide more clinical benefits for patients with endometriosis-associated pain.

My notes (saved in your browser only)

Outcome instruments

EHP-30 VAS-pain

Condition tags

endometriosisdysmenorrheadyspareunia

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (48)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK